Novo Nordisk (CPSE:NOVO B): Assessing Valuation After Trump’s Drug Price Push and Strategic Expansion
Shares in Novo Nordisk (CPSE:NOVO B) moved sharply this week after President Trump announced plans to lower U.S. prices for weight-loss and diabetes drugs like Ozempic. The announcement prompted heightened volatility and renewed investor questions about the company’s future profit outlook.
See our latest analysis for Novo Nordisk.
Novo Nordisk’s share price has been on a roller coaster, down over 46% year-to-date and recently tumbling after U.S. policy signals on drug pricing, despite headline-making deals such as acquiring rights to the rare-disease therapy zaltenibart. While momentum has faded in the short term, a 5-year total shareholder return of nearly 68% shows the franchise’s enduring strength even as competition and…
